KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EBT (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of EBT data on record, last reported at -$40.2 million in Q4 2025.

  • For Q4 2025, EBT fell 1594.94% year-over-year to -$40.2 million; the TTM value through Dec 2025 reached -$546.1 million, down 76.41%, while the annual FY2025 figure was -$546.1 million, 76.41% down from the prior year.
  • EBT reached -$40.2 million in Q4 2025 per PACB's latest filing, down from -$37.6 million in the prior quarter.
  • Across five years, EBT topped out at $2.7 million in Q4 2024 and bottomed at -$426.4 million in Q1 2025.
  • Average EBT over 5 years is -$85.6 million, with a median of -$74.2 million recorded in 2022.
  • Peak YoY movement for EBT: soared 103.25% in 2024, then plummeted 1594.94% in 2025.
  • A 5-year view of EBT shows it stood at -$68.2 million in 2021, then decreased by 23.81% to -$84.4 million in 2022, then grew by 1.95% to -$82.7 million in 2023, then skyrocketed by 103.25% to $2.7 million in 2024, then crashed by 1594.94% to -$40.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$40.2 million in Q4 2025, -$37.6 million in Q3 2025, and -$41.9 million in Q2 2025.